Aparna Kalyan, MD | Northwestern Medicine

Dr. Aparna Kalyan

Claim this profile

Northwestern University

Studies Bile Duct Cancer
Studies Pancreatic Cancer
22 reported clinical trials
40 drugs studied

About Aparna Kalyan

Education:

  • Earned an MD from Flinders University of South Australia in 2005.
  • Completed Residency at The MetroHealth System/Case Western Reserve University in 2011.
  • Completed Fellowships at UPMC Medical Education (2014) and McGaw Medical Center of Northwestern University (2015).

Experience:

  • Associate Professor at the Feinberg School of Medicine, Northwestern University.
  • Focuses on treating a variety of cancers, including anal, colon, esophageal, gastrointestinal, liver, pancreatic, rectal, small bowel, and stomach cancers.
  • Board-certified in Internal Medicine and Medical Oncology by the American Board of Internal Medicine.

Area of expertise

1Bile Duct Cancer
Aparna Kalyan has run 7 trials for Bile Duct Cancer. Some of their research focus areas include:
Stage IV
Stage III
RAF positive
2Pancreatic Cancer
Aparna Kalyan has run 7 trials for Pancreatic Cancer. Some of their research focus areas include:
Stage IV
Stage III
BRCA1 positive

Affiliated Hospitals

Image of trial facility.
Northwestern University
Image of trial facility.
Northwestern Medicine Lake Forest Hospital

Clinical Trials Aparna Kalyan is currently running

Image of trial facility.

Chemotherapy vs Chemoradiotherapy

for Rectal Cancer

This study is being done to answer the following questions: Is the chance of rectal cancer responding the same if chemotherapy alone is given before limited surgery compared to chemotherapy and radiation therapy given together before limited surgery? If radiation therapy is not given, is quality of life better?
Recruiting2 awards Phase 3
Image of trial facility.

Nivolumab + Standard Treatment

for Stomach and Esophageal Cancer

This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Adding nivolumab to ramucirumab and paclitaxel may work better to treat patients with advanced stomach or esophageal cancer.
Recruiting1 award Phase 2 & 320 criteria

More about Aparna Kalyan

Clinical Trial Related3 years of experience running clinical trials · Led 22 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments Aparna Kalyan has experience with
  • Nivolumab
  • Oxaliplatin
  • Fluorouracil
  • Cabozantinib
  • Ipilimumab
  • Nab-paclitaxel

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Aparna Kalyan specialize in?
Is Aparna Kalyan currently recruiting for clinical trials?
Are there any treatments that Aparna Kalyan has studied deeply?
What is the best way to schedule an appointment with Aparna Kalyan?
What is the office address of Aparna Kalyan?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security